Renalytix PLC (RNLX)
0.5117
-0.08
(-13.11%)
USD |
NASDAQ |
May 17, 16:00
0.5149
0.00 (0.00%)
After-Hours: 04:40
Renalytix Debt to Equity Ratio: -0.8407 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.8407 |
| December 31, 2023 | 3.140 |
| September 30, 2023 | -6.987 |
| June 30, 2023 | 1.715 |
| March 31, 2023 | 0.6312 |
| December 31, 2022 | 1.348 |
| September 30, 2022 | 0.5775 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.4032 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.0006 |
| March 31, 2021 | 0.0032 |
| December 31, 2020 | 0.0029 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-6.987
Minimum
Sep 2023
3.140
Maximum
Dec 2023
-0.0004
Average
0.003
Median
Debt to Equity Ratio Benchmarks
| TC BioPharm (Holdings) PLC | -- |
| Ainos Inc | 0.2505 |
| Aptorum Group Ltd | -- |
| Adaptimmune Therapeutics PLC | 0.00 |
| Biodexa Pharmaceuticals Plc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 8.769M |
| Total Liabilities (Quarterly) | 19.88M |
| Shareholders Equity (Quarterly) | -11.11M |
| Current Ratio | 0.423 |
| Net Debt Paydown Yield | 1.02% |